

We claim:

1. A pharmaceutical composition comprising
tirzepatide, or a pharmaceutically acceptable salt thereof;
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
dibasic sodium phosphate at a concentration from 0.67 mg/mL to 2.68 mg/mL.
2. A pharmaceutical composition as claimed in Claim 1 wherein the
tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is
from 5 to 30 mg/mL.
3. A pharmaceutical composition as claimed in Claim 1 wherein the dibasic
sodium phosphate concentration is 1.34 mg/mL.
4. A pharmaceutical composition as claimed in Claim 1 wherein the
tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is
selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL.
5. A pharmaceutical composition as claimed in Claim 4 wherein the
tirzepatide, or pharmaceutically acceptable salt thereof, concentration is
selected from the group consisting of 10, 20, and 30 mg/mL.
6. A pharmaceutical composition as claimed in Claim 1 wherein the
concentration of NaCl is from 7.0 mg/mL to 9.0 mg/mL.
7. A pharmaceutical composition as claimed in Claim 6 wherein the NaCl
concentration is 8.2 mg/mL.
8. A pharmaceutical composition as claimed in Claim 1 wherein tirzepatide,
or pharmaceutically acceptable salt thereof, concentration is from 5
mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is from 0.67
mg/mL to 2.68 mg/mL; and NaCl concentration is from 6.2 mg/mL to 9.5
mg/mL.
9. A pharmaceutical composition as claimed in Claim 8 wherein tirzepatide,
or pharmaceutically acceptable salt thereof, concentration is from 5

mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is 1.34 mg/mL; and NaCl concentration is 8.2 mg/mL.

10. A pharmaceutical composition as claimed in Claim 9 wherein the composition is presented in an automatic injection apparatus.
11. A pharmaceutical composition as claimed in Claim 1 wherein the pH of the composition is from 6.5 to 7.5.
12. A pharmaceutical composition as claimed in Claim 11 wherein the pH is from 6.7 to 7.3.

Dated this on 21st day of November, 2020.



SACHIN BINDAL
OF K & S PARTNERS
AGENT FOR THE APPLICANT(S)
IN/PA-2560
Digitally signed and filed through e-filing